MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI), announced today that it initiated a Phase IIb clinical trial evaluating Capesaris™, a selective estrogen receptor alpha agonist, compared to Lupron Depot® (leuprolide acetate for depot suspension) for first line treatment of advanced prostate cancer.
